Aceragen Inc | IDRA

Aceragen Inc traded at $2.66 this Wednesday March 22nd, decreasing $0.35 or 11.63 percent since the previous trading session. Looking back, over the last four weeks, Aceragen Inc lost 47.01 percent. Over the last 12 months, its price fell by 70.36 percent. Looking ahead, we forecast Aceragen Inc to be priced at 3.46 by the end of this quarter and at 3.14 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Abbott 96.86 -1.47 -1.50% -17.16%
Agenus 1.52 -0.11 -6.75% -43.28%
Alnylam Pharmaceuticals 189.74 -0.69 -0.36% 16.87%
Amgen 229.83 -3.12 -1.34% -1.86%
Biogen 261.22 -4.93 -1.85% 24.62%
BioMarin Pharmaceutical 90.08 -2.00 -2.17% 11.40%
CytrRx Corporation 0.08 -0.01 -11.22% -80.51%
Dynavax Technologies 9.62 -0.34 -3.41% -13.80%
Gilead Sciences 77.81 -1.33 -1.68% 31.57%
GlaxoSmithKline 1,438.40 10.40 0.73% -10.80%
Aceragen Inc 2.66 -0.35 -11.63% -70.36%
Eli Lilly 330.97 -0.11 -0.03% 15.04%
Merck & Co 104.40 -1.14 -1.08% 30.94%
Mirati Therapeutics 39.54 -1.18 -2.90% -52.01%
Nektar Therapeutics 0.79 -0.09 -9.73% -87.22%
Pfizer 40.01 -0.65 -1.60% -23.34%
Ultragenyx Pharmaceutical 37.28 -1.06 -2.76% -45.79%
Roche Holding 261.15 -1.55 -0.59% -28.56%
Seattle Genetics 198.37 -1.54 -0.77% 42.99%
Sarepta Therapeutics 129.11 -2.06 -1.57% 61.15%
X T L Biopharmaceuticals 1.18 -0.10 -7.80% -47.08%

Indexes Price Day Year
USND 11670 -190.15 -1.60% -16.18%
US2000 1727 -50.38 -2.83% -15.83%

Aceragen Inc
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.